In Q3 2023, Tang Capital Management held 68 positions worth $500.2M. They initiated 12 new positions and exited 19. Their largest holding was TARS ($38.0M). Portfolio value grew +2.8% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q3 2023?
Tang Capital Management held 68 biotech stocks in their 13F portfolio in Q3 2023. Their top positions include TARS, MIRM, ANAB, KALV, EOLS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q3 2023?
Tang Capital Management's tracked biotech portfolio was worth $500.2M across 68 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q3 2023?
Tang Capital Management initiated 12 new positions in Q3 2023, including NTLA, QURE, DSGN, RCKT, CBAY and 7 more. They also increased 14 existing positions.
What did Tang Capital Management sell in Q3 2023?
Tang Capital Management fully exited 19 positions in Q3 2023, including VNDA, SCYX, RXDX, ITOS, TIL and 14 more. They also trimmed 7 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Management portfolio →